Tempus AI, Inc. has announced a significant step in its business strategy by entering into a series of agreements with Bristol-Myers Squibb Company (BMS) and Pathos AI, Inc. This collaboration aims to expand the use of Tempus's multimodal real-world data, data analysis software, and machine learning models, particularly in the fields of oncology and neurology. The agreements are expected to provide Tempus with substantial financial benefits, totaling $192.5 million over the next five years.
On October 23, 2026, Tempus disclosed these agreements in a filing with the Securities and Exchange Commission. This strategic move is crucial for Tempus as it seeks to enhance its data offerings and strengthen its market position in the competitive landscape of data processing services.
Background
Tempus AI, Inc. is a company incorporated in Nevada, primarily focused on providing data processing and computer programming services. The company operates under the Standard Industrial Classification (SIC) code 7370, which pertains to services related to computer programming and data processing. Tempus is listed on the Nasdaq under the ticker symbol TEM. The company has a history of leveraging advanced technologies to analyze and utilize data in healthcare, particularly in oncology.
What the Filing Says
The SEC filing reveals that Tempus has entered into an Oncology Data License and Related Services Agreement with BMS, which includes a Statement of Work (Onco SOW) that allows BMS to access Tempus's de-identified oncology dataset. The Onco SOW will provide BMS with access to multimodal records and analytical tools, including Tempus's Lens software application. The agreement guarantees Tempus $137.5 million in fixed payments over its term, which extends to December 31, 2031.
Additionally, Tempus has established a Neuro Order Form with Pathos, which will allow Pathos to access 500,000 de-identified records of patients diagnosed with neurological conditions, including Alzheimer’s disease. This agreement is expected to generate up to $55 million for Tempus, based on the delivery of records over the five-year period.
Impact
This development is significant for Tempus as it not only secures a substantial cash inflow but also enhances its data capabilities in oncology and neurology. The agreements may positively affect Tempus's operational capacity and market reach. The collaboration with BMS and Pathos could also influence other companies in the data processing sector, prompting them to explore similar partnerships or innovations in data analytics.
What's Next
The filing does not specify what happens next, but it indicates that Tempus will continue to fulfill its obligations under the agreements with BMS and Pathos. The company is expected to leverage this opportunity to further develop its data services and potentially attract additional partnerships in the future.